NxStage Medical, Inc. Shares Spiked After Acquisition Agreement

Published on: 07 Aug, 2017

NxStage Medical, Inc. (NASDAQ: NXTM) shares jumped 27% Monday, after the medical technology company announced  that its Board of Directors has unanimously approved a definitive agreement under which Fresenius Medical Care will acquire all of the outstanding shares of NxStage for $30.00 per share in a cash transaction valued at approximately $2 billion.

"I am very proud of the impact NxStage continues to have on advancing the standard of renal care for patients around the world," stated Jeffrey H. Burbank, Founder and CEO of NxStage. "We believe that the announced transaction with Fresenius Medical Care creates significant value for our shareholders and significant opportunities for our patients, customers, partners and employees. I'm excited about what this means for the future of our products and therapy, and for the patients who will receive greater access to them."

The copmany also commneted on the second quarter financial results. In a press release NxxStage Medical indicated that total revenue for the second quarter of 2017 increased 4 percent to $96.2 million, within its guidance range of $95 to $97 million, compared with revenue of $92.2 million for the second quarter of 2016.

The Products Business generated $4.5 million of income from operations for the second quarter of 2017. Net loss attributable to NxStage Medical, Inc.'s stockholders was $2.1 million for the second quarter of 2017 compared with a net loss of $1.7 million for the second quarter of 2016.

Ratings

Ratings
  • 902Views
  • 0Comments

Recommend to Friends

  • facebook
  • Twitter
  • google plus
  • pinterest
  • Digg
  • stumbleupon
  • Reddit
  • linkedin

Danny Abramov

Email: danny@financialinsiders.com

@Newsletter

Sign Up for Weekly Updates

Related Posts

02 Jun, 2017 895
28 Jul, 2017 1140
31 Aug, 2017 1279
29 Sep, 2017 827

Comments

There is no comment on this article